Building Thailand’s Biosimilar Industry From The Ground Up
Building Thailand’s Biosimilar Industry From The Ground Up

As the first of this two-part article revealed, the biosimilar market has undergone several revolutions since the release of the Thai FDA’s biosimilar guidelines in 2013. During our tour of Siam’s facilities, the company’s managing director, Songpon Deechongkit, Ph.D., shared the company’s history, overall biosimilar strategy, and some of the pros and cons of being the first and only biosimilar company in Thailand.

  • Integrating The Payer Perspective Into Drug Development
    Integrating The Payer Perspective Into Drug Development

    In the last decade, the healthcare industry has witnessed significant changes, some of which present important challenges to how pharmaceutical companies develop drugs. One such challenge is the shift in influence from the physician to the payer in the adoption of new interventions. This article discusses threats to the traditional model of drug development posed by the increasing influence of payers and considers ways for industry to embrace “value-focused development” to simultaneously adapt to the evolving market and de-risk drug development.

  • 5 Tips For Orphan Drug Development In A Price-Sensitive Payer Environment
    5 Tips For Orphan Drug Development In A Price-Sensitive Payer Environment

    The first installment in this two-part series examined rising costs associated with orphan drugs and two related case studies. This second part provides actionable suggestions for developers.

  • Supreme Court’s Amgen v. Sandoz Decision: More Questions Than Answers?
    Supreme Court’s Amgen v. Sandoz Decision: More Questions Than Answers?

    On June 12, the Supreme Court issued a unanimous opinion in Amgen v. Sandoz, penned by Justice Clarence Thomas. The Court addressed two questions, stemming from the Federal Circuit’s 2015 decision in the case, on which certiorari had been granted.

  • A Deep Dive Into Brazil’s Biosimilar PDPs
    A Deep Dive Into Brazil’s Biosimilar PDPs

    In terms of life sciences, Brazil is best known as a small molecule pharmaceutical market; some of the largest companies in Brazil are small molecule generics companies. But, in recent years, the country has identified the importance of establishing a biotechnology industry. Enter the productive development partnerships (PDPs). 

  • Chinese & Indian Expectations For GMP Biologics Exports — A Comparative Assessment
    Chinese & Indian Expectations For GMP Biologics Exports — A Comparative Assessment

    In our studies we asked respondents to indicate their facility’s primary objectives for biologics production today and in 10 years. We found that in China, 70 percent of biopharma facilities today are primarily focused on production for domestic consumption.

  • 5 Biosimilar Questions: The Payer Perspective (Part 2)
    5 Biosimilar Questions: The Payer Perspective (Part 2)

    In this article (the second of two parts), experts from a regional and national payer elaborate on some of their expectations for the market and how they — in partnership with companies — can encourage biosimilar acceptance.

  • 5 Biosimilar Questions: The Payer Perspective (Part 1)
    5 Biosimilar Questions: The Payer Perspective (Part 1)

    In the first of this two-part article, two experts from a regional and national payer reveal why they haven't exactly taken the hoped-for no-holds-barred approach to biosimilars.

  • Pharma's Vital Interest In Tracking State Biosimilar Substitution Laws
    Pharma's Vital Interest In Tracking State Biosimilar Substitution Laws

    State lawmakers continue to spearhead legislative boundaries to automatic biosimilar substitution at a rapid clip across the nation, with 33 states and Puerto Rico having taken action and with bills pending in eight more states.

  • The Importance Of Options In Biosimilar Litigation
    The Importance Of Options In Biosimilar Litigation

    A recent discussion amongst experts from Momenta, Eli Lilly, and Foley & Lardner highlighted the diversity of opinions surrounding Amgen v. Sandoz and other legal challenges in the space. But lurking underneath discussions of statutes and standards of evidence is biosimilar makers' desires for options to address the U.S.' rigid patent landscape.

More Biosimilar editorial...

BIOSIMILAR INSIGHTS

  • Autologous Cell Therapies At A Crossroads With The FDA: What Can You Do to Help?

    Regulatory controls on local collection and processing of autologous cells present a major challenge to clinics that want to provide individualized therapies onsite. What does the pharmaceutical industry need to know — and, more importantly, do — to overcome it?

  • Best Practices In Formulation And Lyophilization Development

    The ultimate goal of formulation development is a stable product. In the case of a protein product, that can be defined as delivering the correct dose, in the native secondary and tertiary structure, without unintended chemical modifications, and free of extrinsic and intrinsic particles. In many cases, a lyophilized formulation can provide the highest probability of technical success. A well-designed product development plan can develop a phase 1 product quickly, while laying the foundation for commercial product success.

  • 5 Key Considerations For Successfully Creating cGMP Single-Use Biomanufacturing Capacity

    Single-use technologies are being seen as the solution to flexibly and cost-effectively address many of the challenges around creating biologics manufacturing capacity.

  • The Biggest Mistake You Can Make With Continuous Manufacturing And The FDA

    To allay fears about manufacturing changes, valuable tools are now in places by the FDA to facilitate these transitions. By not understanding the availability and value of these resources, manufacturers are making a sizeable mistake that could potentially impede the industry’s passage into the next phase of modernized manufacturing.

  • 5 Key Considerations To Future-Proof Your Single-Use Biomanufacturing Capacity

    The plug-and-play nature of single-use enables you to incorporate new technologies and innovations into the process workflow as they become available. But beyond the flexibility of the single-use platform, you need to consider a range of other factors to ensure your capacity can will meet your long-term needs.

More From Biosimilar...

TRAINING COURSES

Simplifying Your Quality System While Implementing ISO 13485:2016 Requirements – Strategies for Success July 27, 2017
1pm-2:30pm EDT, Online Training
Duration:  90 Minutes
Price:  $299 - Includes Bonus Handouts!
Drug Development 101 – How A Drug Is Made August 3, 2017
1pm-2:30pm EDT, Online Training
Duration:  90 Minutes
Price:  $299 - Includes Bonus Handouts!
ICH E6 Addendum R2 Team Training and Action Planning August 7, 2017
11:00am- 12:00pm EDT, Online Training
Duration:  60 Minutes
Price:  $299 - Includes Bonus Handouts!
Cell Therapy: Process Design Considerations To Support Commercialization August 9, 2017
1pm-2:30pm EDT, Online Training
Duration:  90 Minutes
Price:  $299 - Includes Bonus Handouts!
Effective Batch Record Review - Getting It Right The First Time August 14, 2017
1pm-2:30pm EDT, Online Training
Price:  $299 - Includes Bonus Handouts!
CAPA and Root Cause Analysis Essentials Post ICH GCP E6 (R2) Addendum August 21, 2017
11:00am- 12:00pm EDT, Online Training
Duration:  60 Minutes
Price:  $299 - Includes Bonus Handouts!
How To Establish The Number of Runs Required For Process Validation August 23, 2017
1:00 - 2:00 PM EDT, Online Training
Duration:  60 Minutes
Price:  $299 - Includes Bonus Handouts!
Monitoring Plan Development: Post ICH GCP E6 (R2) Addendum August 25, 2017
11:00am- 12:00pm EDT, Online Training
Duration:  60 Minutes
Price:  $299 - Includes Bonus Handouts!
EU vs. US GMP: Understanding Major Differences Post FDA/EMA Mutual Recognition Agreement September 6, 2017
1pm-2:30pm EDT, Online Training
Duration:  90 Minutes
Price:  $299 - Includes Bonus Handouts!
Conducting an Effective GCP Audit of a CRO-Managed Ongoing Study: Tips and Suggestions September 7, 2017
1:00 - 2:30 PM EDT, Online Training
Duration:  90 Minutes
Price:  $299 - Includes Bonus Handouts!
More Upcoming Courses
Anna Rose Welch article header

 EVENTS

Simplifying Your Quality System While Implementing ISO 13485:2016 Requirements – Strategies for Success July 27, 2017
1pm-2:30pm EDT, Online Training
Duration:  90 Minutes
Price:  $299 - Includes Bonus Handouts!
Drug Development 101 – How A Drug Is Made August 3, 2017
1pm-2:30pm EDT, Online Training
Duration:  90 Minutes
Price:  $299 - Includes Bonus Handouts!
ICH E6 Addendum R2 Team Training and Action Planning August 7, 2017
11:00am- 12:00pm EDT, Online Training
Duration:  60 Minutes
Price:  $299 - Includes Bonus Handouts!
Cell Therapy: Process Design Considerations To Support Commercialization August 9, 2017
1pm-2:30pm EDT, Online Training
Duration:  90 Minutes
Price:  $299 - Includes Bonus Handouts!
Effective Batch Record Review - Getting It Right The First Time August 14, 2017
1pm-2:30pm EDT, Online Training
Price:  $299 - Includes Bonus Handouts!

LIFE SCIENCE EVENTS

Drug Development 101 – How A Drug Is Made August 3, 2017
1pm-2:30pm EDT, Online Training
ICH E6 Addendum R2 Team Training and Action Planning August 7, 2017
11:00am- 12:00pm EDT, Online Training
Cell Therapy: Process Design Considerations To Support Commercialization August 9, 2017
1pm-2:30pm EDT, Online Training
Effective Batch Record Review - Getting It Right The First Time August 14, 2017
1pm-2:30pm EDT, Online Training
More Events...

LIFE SCIENCE INDUSTRY EVENTS

Drug Development 101 – How A Drug Is Made August 3, 2017
1pm-2:30pm EDT, Online Training
ICH E6 Addendum R2 Team Training and Action Planning August 7, 2017
11:00am- 12:00pm EDT, Online Training
Cell Therapy: Process Design Considerations To Support Commercialization August 9, 2017
1pm-2:30pm EDT, Online Training
Effective Batch Record Review - Getting It Right The First Time August 14, 2017
1pm-2:30pm EDT, Online Training
More Industry Events

ABOUT BIOSIMILAR DEVELOPMENT

Biosimilar Development is dedicated to presenting technical information, thought leadership, and commentary for the biosimilar development and manufacturing community. On this site, users will find exclusive and actionable content on the industry trends and challenges affecting the emerging biosimilars market. Browse our articles, case studies, and white papers on topics related to biosimilar development, manufacturing, quality, distribution, FDA guidance, BPCIA, global markets, government regulations, and intellectual property.

Biosimilar Development is part of the Life Science Connect media group, which strives to facilitate connections and foster collaborations in pharmaceutical development to find ways to get more life-saving and life-improving therapies to market. Connect, Collaborate, Contribute.